STOCK TITAN

Sensus Healthcare Q3 2026 revenue falls 13% to $6M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Sensus Healthcare, Inc. (SRTS) reported third-quarter 2026 revenue of $6.0 million, down 13.0% from $6.9 million a year earlier. Gross profit rose 22.2% to $3.3 million and gross margin was 55.0%, versus 39.1%; net loss was $1.493 million, versus $0.943 million. Management attributed lower revenue mainly to product mix and no current-quarter sales to a historically large customer. The company shipped 26 systems, including 8 units backlogged from the second quarter, versus 16 a year earlier. Three systems shipped during the quarter were under Fair Deal Agreement and rental arrangements, with revenue recognized over the agreement term.

For the nine months ended September 30, revenue fell 48.0% to $11.7 million from $22.5 million, gross profit was $5.0 million versus $10.0 million, and net loss was $12.868 million versus $4.552 million. Operating cash flow was a $9.147 million outflow, versus $2.735 million provided a year earlier; cash, restricted cash and equivalents totaled $12.920 million at September 30, 2026. The new CNB facility provides for maximum borrowings of $15.0 million, with borrowing limited to $2.0 million during its initial term and the remaining $13.0 million commitment restricted; no borrowings were outstanding at September 30. Management believes cash on hand and maturing cash equivalents are sufficient for the next 12 months.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

How the balance works

Positive

  • Moderate pointThird-quarter gross profit increased 22.2% to $3.3 million.

Negative

  • Major pointNine-month revenue fell 48.0% to $11.7 million.
  • Moderate pointNine-month net loss reached $12.868 million, versus $4.552 million.
  • Moderate pointOperating cash flow was $9.147 million used, versus $2.735 million provided.
  • Minor pointThird-quarter revenue declined 13.0% to $6.0 million.

Filing Explained

A rental program begun in July 2026 provides upfront funding to Sensus after delivery and customer acceptance, while EverBank takes title; Sensus accounts for the equipment as an operating lease, recognizes its allocated consideration over the original term, and may reacquire it for $1 subject to conditions.

Third-quarter revenue $6.0 million Three months ended September 30, 2026; $6.9 million in 2025, a 13.0% decrease.
Nine-month revenue $11.7 million Nine months ended September 30, 2026; $22.5 million in 2025, a 48.0% decrease.
Third-quarter gross profit $3.3 million Three months ended September 30, 2026; $2.7 million in 2025, an increase of 22.2%.
Third-quarter net loss $1.493 million Three months ended September 30, 2026; $0.943 million in 2025.
Nine-month net loss $12.868 million Nine months ended September 30, 2026; $4.552 million in 2025.
Net cash used in operating activities $9.147 million used Nine months ended September 30, 2026; $2.735 million provided in 2025.
Cash, restricted cash and cash equivalents $12.920 million As of September 30, 2026.
CNB facility maximum borrowings $15.0 million Maximum borrowings under the facility entered into on June 2, 2026.
superficial radiation therapy medical
"proprietary low-energy X-ray technology known as superficial radiation therapy"
Fair Deal Agreement technical
"the term the Company uses for this service model is the “Fair Deal Agreement”"
full valuation allowance financial
"continued recognition of a full valuation allowance against the Company's net deferred tax assets"
debt service coverage ratio financial
"maintain a minimum debt service coverage ratio of 1.50"
Debt service coverage ratio measures how many times a company's available cash flow can pay its scheduled debt payments (interest plus principal). Think of it like checking how many months of take-home pay it would take to cover your mortgage and loan bills; a higher number means a bigger cushion against missed payments. Investors use it to gauge credit risk, the likelihood of default, and whether a company can afford dividends or new borrowing.
Secured Overnight Financing Rate financial
"interest at the Secured Overnight Financing Rate plus 3.00%"
A secured overnight financing rate (SOFR) is a daily benchmark interest rate that reflects the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Think of it as the market price to “rent” cash for a day with a very safe pledge, similar to paying a short-term rental fee for money backed by government bonds. Investors track SOFR because it underpins pricing for loans, bonds and derivatives, so movements change borrowing costs, interest income and the valuation of interest-rate–linked positions.
remaining performance obligations financial
"Estimated service revenue to be recognized in the future related to the performance obligations"
Remaining performance obligations are the work a company still needs to complete for its customers, like finishing a service or delivering a product. It’s important because it shows how much future income the company has coming in from current agreements, giving a clearer picture of its ongoing business.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was SRTS revenue in the third quarter of 2026?

SRTS reported revenue of $6.0 million for the three months ended September 30, 2026, compared with $6.9 million a year earlier. Gross profit was $3.3 million versus $2.7 million, and net loss was $1.493 million versus $0.943 million.

What were SRTS’s financial results for the first nine months of 2026?

SRTS reported nine-month revenue of $11.7 million, compared with $22.5 million in the prior-year period. Gross profit was $5.0 million versus $10.0 million, net loss was $12.868 million versus $4.552 million, and operating cash flow was a $9.147 million outflow versus $2.735 million provided.

How does Sensus Healthcare’s equipment-rental program work?

The program, which began in July 2026, uses EverBank, N.A. as the third-party funder. After equipment delivery and customer acceptance, EverBank provides Sensus with funding equal to the equipment price and acquires title; EverBank collects customer payments during the rental. Sensus may reacquire the equipment for $1 at the end of the original lease term, subject to specific conditions.

What conditions apply to the SRTS CNB credit facility?

The facility matures on June 5, 2027, unless extended by mutual agreement. If it is renewed and CNB makes the remaining $13.0 million commitment available, Sensus must maintain a 1.50 minimum debt service coverage ratio, tested quarterly beginning with the first fiscal quarter after that availability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 2026 Q3 0001494891 0 1466 4079 2079 0001494891 2026-01-01 2026-09-30 0001494891 2026-11-10 0001494891 2026-09-30 0001494891 2025-12-31 0001494891 2026-07-01 2026-09-30 0001494891 2025-07-01 2025-09-30 0001494891 2025-01-01 2025-09-30 0001494891 us-gaap:CommonStockMember 2024-12-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001494891 us-gaap:TreasuryStockCommonMember 2024-12-31 0001494891 us-gaap:RetainedEarningsMember 2024-12-31 0001494891 2024-12-31 0001494891 us-gaap:CommonStockMember 2025-03-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001494891 us-gaap:TreasuryStockCommonMember 2025-03-31 0001494891 us-gaap:RetainedEarningsMember 2025-03-31 0001494891 2025-03-31 0001494891 us-gaap:CommonStockMember 2025-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001494891 us-gaap:TreasuryStockCommonMember 2025-06-30 0001494891 us-gaap:RetainedEarningsMember 2025-06-30 0001494891 2025-06-30 0001494891 us-gaap:CommonStockMember 2025-12-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001494891 us-gaap:TreasuryStockCommonMember 2025-12-31 0001494891 us-gaap:RetainedEarningsMember 2025-12-31 0001494891 us-gaap:CommonStockMember 2026-03-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001494891 us-gaap:TreasuryStockCommonMember 2026-03-31 0001494891 us-gaap:RetainedEarningsMember 2026-03-31 0001494891 2026-03-31 0001494891 us-gaap:CommonStockMember 2026-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001494891 us-gaap:TreasuryStockCommonMember 2026-06-30 0001494891 us-gaap:RetainedEarningsMember 2026-06-30 0001494891 2026-06-30 0001494891 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001494891 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001494891 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001494891 2025-01-01 2025-03-31 0001494891 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001494891 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001494891 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001494891 2025-04-01 2025-06-30 0001494891 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001494891 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001494891 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001494891 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001494891 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001494891 2026-01-01 2026-03-31 0001494891 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001494891 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001494891 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001494891 2026-04-01 2026-06-30 0001494891 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001494891 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001494891 us-gaap:CommonStockMember 2025-09-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2025-09-30 0001494891 us-gaap:RetainedEarningsMember 2025-09-30 0001494891 2025-09-30 0001494891 us-gaap:CommonStockMember 2026-09-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2026-09-30 0001494891 us-gaap:RetainedEarningsMember 2026-09-30 0001494891 us-gaap:ProductMember 2026-07-01 2026-09-30 0001494891 us-gaap:ProductMember 2025-07-01 2025-09-30 0001494891 us-gaap:ProductMember 2026-01-01 2026-09-30 0001494891 us-gaap:ProductMember 2025-01-01 2025-09-30 0001494891 srts:ProductRevenueMember 2026-07-01 2026-09-30 0001494891 srts:ProductRevenueMember 2025-07-01 2025-09-30 0001494891 srts:ProductRevenueMember 2026-01-01 2026-09-30 0001494891 srts:ProductRevenueMember 2025-01-01 2025-09-30 0001494891 us-gaap:ServiceMember 2026-07-01 2026-09-30 0001494891 us-gaap:ServiceMember 2025-07-01 2025-09-30 0001494891 us-gaap:ServiceMember 2026-01-01 2026-09-30 0001494891 us-gaap:ServiceMember 2025-01-01 2025-09-30 0001494891 srts:ServiceRevenueMember 2026-07-01 2026-09-30 0001494891 srts:ServiceRevenueMember 2025-07-01 2025-09-30 0001494891 srts:ServiceRevenueMember 2026-01-01 2026-09-30 0001494891 srts:ServiceRevenueMember 2025-01-01 2025-09-30 0001494891 us-gaap:ProductMember 2025-12-31 0001494891 us-gaap:ServiceMember 2025-12-31 0001494891 us-gaap:ProductMember 2026-09-30 0001494891 us-gaap:ServiceMember 2026-09-30 0001494891 srts:ServiceRevenueMember 2026-09-30 0001494891 srts:USCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001494891 srts:USCustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001494891 srts:USCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001494891 srts:USCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001494891 srts:USCustomerMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001494891 srts:USCustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-09-30 0001494891 srts:USCustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-09-30 0001494891 srts:USCustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-09-30 0001494891 srts:USCustomerFourMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2026-09-30 0001494891 srts:USCustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-12-31 0001494891 country:US 2026-07-01 2026-09-30 0001494891 country:US 2025-07-01 2025-09-30 0001494891 country:CN 2026-07-01 2026-09-30 0001494891 country:CN 2025-07-01 2025-09-30 0001494891 srts:OtherMember 2026-07-01 2026-09-30 0001494891 srts:OtherMember 2025-07-01 2025-09-30 0001494891 country:US 2026-01-01 2026-09-30 0001494891 country:US 2025-01-01 2025-09-30 0001494891 country:CN 2026-01-01 2026-09-30 0001494891 country:CN 2025-01-01 2025-09-30 0001494891 srts:OtherMember 2026-01-01 2026-09-30 0001494891 srts:OtherMember 2025-01-01 2025-09-30 0001494891 srts:EarningsPerShareMember 2026-07-01 2026-09-30 0001494891 srts:EarningsPerShareMember 2025-07-01 2025-09-30 0001494891 srts:EarningsPerShareMember 2026-01-01 2026-09-30 0001494891 srts:EarningsPerShareMember 2025-01-01 2025-09-30 0001494891 srts:RestrictedStockawardsMember 2026-07-01 2026-09-30 0001494891 srts:RestrictedStockawardsMember 2025-07-01 2025-09-30 0001494891 srts:RestrictedStockawardsMember 2026-01-01 2026-09-30 0001494891 srts:RestrictedStockawardsMember 2025-01-01 2025-09-30 0001494891 srts:StockOptionsMember 2026-07-01 2026-09-30 0001494891 srts:StockOptionsMember 2025-07-01 2025-09-30 0001494891 srts:StockOptionsMember 2026-01-01 2026-09-30 0001494891 srts:StockOptionsMember 2025-01-01 2025-09-30 0001494891 us-gaap:EquipmentMember 2026-09-30 0001494891 us-gaap:EquipmentMember 2025-12-31 0001494891 us-gaap:EquipmentMember srt:MinimumMember 2026-09-30 0001494891 us-gaap:EquipmentMember srt:MaximumMember 2026-09-30 0001494891 srts:EquipmentLeasedToCustomersMember 2026-09-30 0001494891 srts:EquipmentLeasedToCustomersMember 2025-12-31 0001494891 srts:TradeshowAndDemoEquipmentMember 2026-09-30 0001494891 srts:TradeshowAndDemoEquipmentMember 2025-12-31 0001494891 us-gaap:ComputerEquipmentMember 2026-09-30 0001494891 us-gaap:ComputerEquipmentMember 2025-12-31 0001494891 us-gaap:ResearchAndDevelopmentArrangementMember 2026-09-30 0001494891 us-gaap:ResearchAndDevelopmentArrangementMember 2025-12-31 0001494891 srts:CNBCreditFacilityMember 2026-06-02 0001494891 srts:InitialTermMember 2026-06-02 0001494891 srts:RestrictedCommitmentMember 2026-06-02 0001494891 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2026-01-01 2026-09-30 0001494891 2026-06-02 0001494891 srts:RemainingCommitmentMember 2026-06-02 0001494891 srts:CNBCreditFacilityMember 2026-09-30 0001494891 srts:OperatingLeaseAgreementsMember 2026-07-01 2026-09-30 0001494891 srts:OperatingLeaseAgreementsMember 2025-07-01 2025-09-30 0001494891 srts:OperatingLeaseAgreementsMember 2026-01-01 2026-09-30 0001494891 srts:OperatingLeaseAgreementsMember 2025-01-01 2025-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-09-30 0001494891 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-30 0001494891 srts:EquityIncentivesPlan2016Member 2026-09-30 0001494891 srts:EquityIncentivesPlan2017Member 2026-09-30 0001494891 srts:EquityIncentivesPlan2017Member 2026-01-01 2026-09-30 0001494891 srts:EquityIncentivePlanMember 2026-09-30 0001494891 srts:EquityIncentivePlanMember 2025-12-31 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember 2022-12-18 2022-12-19 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember 2026-01-01 2026-09-30 0001494891 srts:EquityIncentivePlanDecember192022Member srts:RestrictedCommonStockMember 2026-09-30 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember 2024-01-10 2024-01-11 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember srts:ImmediatelyVestedMember 2024-01-10 2024-01-11 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember srts:OneYearVestedMember 2024-01-10 2024-01-11 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember 2024-12-16 2024-12-17 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember srts:ImmediatelyVestedMember 2024-12-16 2024-12-17 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember srts:ThreeYearVestingMember 2024-12-16 2024-12-17 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember srts:FourYearVestingMember 2024-12-16 2024-12-17 0001494891 srts:EquityIncentivePlanDecember172024Member srts:RestrictedCommonStockMember 2026-09-30 0001494891 srts:EquityIncentivePlanMember srts:RestrictedCommonStockMember 2025-12-11 2025-12-12 0001494891 us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0001494891 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0001494891 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0001494891 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0001494891 us-gaap:RestrictedStockMember 2025-12-31 0001494891 us-gaap:RestrictedStockMember 2026-09-30 0001494891 us-gaap:StockOptionMember 2025-12-31 0001494891 us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001494891 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0001494891 us-gaap:StockOptionMember 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM ____________ TO ____________

 

Commission File Number: 001-37714

 

Sensus Healthcare, Inc. 

(Exact name of registrant as specified in its charter)

 

Delaware   27-1647271
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

851 Broken Sound Pkwy., NW #215, Boca Raton, FL   33487
(Address of principal executive office)   (Zip Code)

 

(561) 922-5808

 (Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   SRTS   The NASDAQ Stock Market, LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an “emerging growth company.” See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒
            Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 10, 2026, there were 16,462,059 shares of the registrant’s common stock outstanding. 

 

 
 

 

SENSUS HEALTHCARE, INC. 

QUARTERLY REPORT ON FORM 10-Q 

TABLE OF CONTENTS

 

    Page
PART I – Financial Information  
     
Item 1. Condensed Consolidated Financial Statements (unaudited) 1
     
  Condensed Consolidated Balance Sheets (unaudited) 1
     
  Condensed Consolidated Statements of Loss (unaudited) 2
     
  Condensed Consolidated Statements of Stockholders’ Equity (unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows (unaudited) 4
     
  Notes to the Condensed Consolidated Financial Statements (unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 24
     
Item 4. Controls and Procedures 24
     
PART II – Other Information  
     
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 25
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
     
Item 3. Defaults Upon Senior Securities 25
     
Item 4. Mine Safety Disclosure 25
     
Item 5. Other Information 25
     
Item 6. Exhibits 26
     
  Signatures 27

 

 
 

 

INTRODUCTORY NOTE

 

Forward-Looking Statements

 

This report includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

 

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this report, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this report as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission.

 

To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

 

Any forward-looking statements that we make in this report speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this report is filed, except as may be required by applicable law.

 

 
 

 

PART I. FINANCIAL INFORMATION

 

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

SENSUS HEALTHCARE, INC.

 CONDENSED CONSOLIDATED BALANCE SHEETS

 

   As of
September 30,
   As of
December 31,
 
(in thousands, except shares and per share data)  2026   2025 
   (unaudited)     
Assets        
Current assets        
Cash, restricted cash, and cash equivalents  $12,920   $22,083 
Accounts receivable, net   1,403    6,041 
Inventories   17,965    14,563 
Prepaid inventory   —    1,522 
Notes receivable, current portion   609    — 
Other current assets   1,687    1,683 
Total current assets   34,584    45,892 
Property and equipment, net   2,662    1,976 
Deferred tax asset   —    4,079 
Operating lease right-of-use assets, net   265    452 
Notes receivable, net of current portion   2,731    352 
Other noncurrent assets   309    288 
Total assets  $40,551   $53,039 
           
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable and accrued expenses  $3,746   $3,343 
Product warranties   302    275 
Operating lease liabilities, current portion   278    262 
Deferred revenue, current portion   785    842 
Total current liabilities   5,111    4,722 
Operating lease liabilities   —    209 
Deferred revenue, net of current portion   —    10 
Total liabilities   5,111    4,941 
Commitments and contingencies   —    — 
Stockholders’ equity        
Preferred stock, 5,000,000 shares authorized and none issued and outstanding   —    — 
Common stock, $0.01 par value – 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at September 30, 2026;  17,056,845 issued and 16,463,809 outstanding at December 31, 2025   169    169 
Additional paid-in capital   46,300    46,090 
Treasury stock, 593,036 shares at cost, at September 30, 2026 and December 31, 2025   (3,876)   (3,876)
(Accumulated deficit) retained earnings   (7,153)   5,715 
Total stockholders’ equity   35,440    48,098 
Total liabilities and stockholders’ equity  $40,551   $53,039 

 

See accompanying notes to the condensed consolidated financial statements (unaudited). 

 

1
 

 

SENSUS HEALTHCARE, INC.

 CONDENSED CONSOLIDATED STATEMENTS OF LOSS 

(unaudited)

 

                       
   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
(in thousands, except shares and per share data)  2026   2025   2026   2025 
                 
Revenues  $5,995   $6,884   $11,679   $22,543 
Cost of sales   2,707    4,171    6,632    12,573 
Gross profit   3,288    2,713    5,047    9,970 
Operating expenses                    
General and administrative   2,253    1,917    6,079    6,111 
Selling and marketing   1,548    1,546    4,319    5,122 
Research and development   1,106    1,819    3,806    5,896 
Total operating expenses   4,907    5,282    14,204    17,129 
Loss from operations   (1,619)   (2,569)   (9,157)   (7,159)
Other income:                    
Interest income, net   126    160    368    528 
Other income, net   126    160    368    528 
Loss before income tax   (1,493)   (2,409)   (8,789)   (6,631)
Provision for (benefit from) income taxes   —    (1,466)   4,079    (2,079)
Net loss  $(1,493)  $(943)  $(12,868)  $(4,552)
Net loss per share – basic  $(0.09)  $(0.06)  $(0.78)  $(0.28)
diluted  $(0.09)  $(0.06)  $(0.78)  $(0.28)
Weighted average number of shares used in                    
computing net loss per share – basic   16,462,059    16,320,036    16,462,255    16,327,233 
diluted   16,462,059    16,320,036    16,462,255    16,327,233 

 

See accompanying notes to the condensed consolidated financial statements (unaudited). 

 

2
 

 

SENSUS HEALTHCARE, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY 

(unaudited)

 

                                  
   Common Stock   Additional Paid-In   Treasury Stock   Retained Earnings (Accumulated     
(in thousands, except shares)  Shares   Amount   Capital   Shares   Amount   Deficit)   Total 
                             
December 31, 2024   17,036,845   $169   $45,795    (541,449)  $(3,571)  $13,434   $55,827 
Stock-based compensation   —    —    79    —    —    —    79 
Stock repurchase   —    —    —    (50,360)   (300)   —    (300)
Net loss   —    —    —    —    —    (2,572)   (2,572)
March 31, 2025   17,036,845   $169   $45,874    (591,809)  $(3,871)  $10,862   $53,034 
Stock-based compensation   —    —    72    —    —    —    72 
Forfeitures of restricted stock awards   (5,000)   —    (5)   —    —    —    (5)
Net loss   —    —    —    —    —    (1,037)   (1,037)
June 30, 2025   17,031,845   $169   $45,941    (591,809)  $(3,871)  $9,825   $52,064 
Stock-based compensation   —    —    73    —    —    —    73 
Net loss   —    —    —    —    —    (943)   (943)
September 30, 2025   17,031,845   $169   $46,014    (591,809)  $(3,871)  $8,882   $51,194 
                                    
December 31, 2025   17,056,845   $169   $46,090    (593,036)  $(3,876)  $5,715   $48,098 
Stock-based compensation   —    —    70    —    —    —    70 
Forfeitures of restricted stock awards   (1,750)   —    —    —    —    —    — 
Net loss   —    —    —    —    —    (2,626)   (2,626)
March 31, 2026   17,055,095   $169   $46,160    (593,036)  $(3,876)  $3,089   $45,542 
Stock-based compensation   —    —    70    —    —    —    70 
Net loss   —    —    —    —    —    (8,749)   (8,749)
June 30, 2026   17,055,095    169    46,230    (593,036)   (3,876)   (5,660)   36,863 
Stock-based compensation   —    —    70    —    —    —    70 
Net loss   —    —    —    —    —    (1,493)   (1,493)
September 30, 2026   17,055,095   $169   $46,300    (593,036)  $(3,876)  $(7,153)  $35,440 

 

See accompanying notes to the condensed consolidated financial statements (unaudited).

 

3
 

 

SENSUS HEALTHCARE, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(unaudited)

 

            
   For the Nine Months Ended 
   September 30, 
(in thousands)  2026   2025 
Cash flows from operating activities        
Net loss  $(12,868)  $(4,552)
Adjustments to reconcile net loss to net cash, restricted cash, and cash equivalents (used in) provided by operating activities:          
Credit loss expense   —    44 
Depreciation   263    283 
Amortization of right-of-use asset   187    179 
Provision for product warranties   209    406 
Stock-based compensation   210    219 
Deferred income taxes   4,079    (2,040)
Changes in operating assets and liabilities:          
Accounts receivable   4,638    10,351 
Notes receivable   (2,988)   (471)
Inventories   (4,335)   (3,713)
Prepaid inventory   1,522    2,006 
Other current assets   (4)   (454)
Other noncurrent assets   (21)   231 
Accounts payable and accrued expenses   403    808 
Operating lease liability   (193)   (179)
Deferred revenue   (67)   73 
Product warranties   (182)   (456)
Net cash (used in) provided by operating activities   (9,147)   2,735 
Cash flows from investing activities          
Acquisition of property and equipment   (16)   (38)
Net cash used in investing activities   (16)   (38)
Cash flows from financing activities          
Repurchase of common stock   —    (300)
Net cash used in financing activities   —    (300)
Net (decrease) increase in cash, restricted cash, and cash equivalents   (9,163)   2,397 
Cash, restricted cash, and cash equivalents – beginning of period   22,083    22,056 
Cash, restricted cash, and cash equivalents – end of period  $12,920   $24,453 
Supplemental disclosure of cash flow information:          
Interest paid  $—   $— 
Income tax paid  $8   $980 
Income tax refunds received  $—   $393 
Supplemental schedule of noncash investing and financing transactions:          
Transfer of inventory to property and equipment  $933   $770 
Lease liability arising from obtaining right-of-use-assets  $—   $111 

 

See accompanying notes to the condensed consolidated financial statements (unaudited).

 

4
 

 

SENSUS HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

 

Note 1 — Organization and Summary of Significant Accounting Policies

 

Description of the Business

 

Sensus Healthcare, Inc. (together with its subsidiaries, unless the context otherwise indicates, “Sensus” or the “Company”) is a manufacturer of radiation therapy devices sold to healthcare providers globally through its distribution and marketing network. The Company operates from its corporate headquarters located in Boca Raton, Florida.

 

In 2024, the Company formed Sensus Healthcare Services, LLC, a wholly owned subsidiary that provides operational healthcare services to dermatology clinics in the form of leased equipment, radiation oncology oversight and physicist oversight, and on-site device operation by radiotherapy technologists where the Company receives a contractual percentage of all superficial radiation therapy (“SRT”) reimbursement to the practice.

 

Basis of Presentation and Principles of Consolidation

 

These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its subsidiaries. Accounts and transactions between consolidated entities have been eliminated.

 

These financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and notes required by GAAP. In the opinion of management, all adjustments considered necessary for a fair presentation of the results have been included. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other period.

 

The condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited financial statements at that date, but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”).

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.

 

Reclassification of Prior Year Presentation

 

Certain prior period amounts related to notes receivable have been reclassified for consistency with the current period presentation. The reclassifications are limited to notes receivables, other current assets, and other noncurrent assets within the condensed consolidated balance sheets and condensed consolidated statements of cash flows, and have no impact on the reported results of operations.

 

5
 

 

Revenue Recognition

 

The Company derives revenue from sales of the Company’s devices and services related to maintaining and repairing the devices as part of a service contract or on an ad-hoc basis without a service contract.

 

The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product, subject to the terms of the relevant warranty. The Company has determined that these warranties do not represent separate performance obligations, as the customer does not have the option to purchase the warranty separately and the warranty does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management’s estimate of the future claims rate.

 

Revenue is recognized upon transfer of control of promised goods or services to customers when the product is shipped or the service is rendered, based on the amount the Company expects to receive in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct.

 

To determine the transaction price for contracts in which a customer promises consideration in a form other than cash, the Company measures the estimated fair value of the noncash consideration at contract inception. If the Company cannot reasonably estimate the fair value of the noncash consideration, the Company measures the consideration indirectly by reference to the stand-alone selling price of the products promised to the customer or class of customer in exchange for the consideration.

 

Our service contracts include maintenance or repair service for device purchases and personnel service to assist in the use and operation of leased-out equipment under lease agreements where the Company is the lessor.

 

The revenues from maintenance or repair service contracts are recognized over the service contract period on a straight-line basis. In the event that a customer does not sign a service contract, but requests maintenance or repair services after the warranty expires, the Company recognizes revenue when the service is rendered. There is no termination provision in the service contract or any penalties in practice for cancellation of the service contract.

 

The revenues from personnel service contracts are recognized in the period during which the work is performed, as the Company has elected the practical expedient under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, to recognize revenue in the amount that the Company has a right to invoice. The service contracts can be terminated by mutual written agreement.

 

The Company has determined that in practice no significant discount is given on service contracts when offered with the device purchase or equipment lease as compared to when sold on a stand-alone basis. The service level provided is identical whether the service contract is purchased on a stand-alone basis or together with the device purchase or equipment lease. The Company may also incur preparation cost to ensure the customer’s space meets the requirement and specifications for the operation of the equipment. The preparation cost is expensed as incurred.

 

The Company also generates revenue from leases in which the Company is the lessor. The Company identifies the lease and non-lease components and allocates the contract consideration on a relative stand-alone selling price basis at lease inception. The Company has elected the practical expedient to combine lease and non-lease components when the components qualify to be combined, and such combined components are accounted for as a lease under ASC 842, Leases. Revenues from non-lease components that are not qualified to be combined are recognized under ASC 606 when the related services are rendered.

 

6
 

 

The components of disaggregated revenue for the three and nine months ended September 30, 2026 and 2025 were as follows:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
(in thousands)  2026   2025   2026   2025 
Product Revenue - recognized at a point in time  $4,818   $4,832   $7,712   $16,930 
Product Revenue - recognized over time   401    530    1,068    1,087 
Service Revenue - recognized at a point in time   463    633    1,381    1,983 
Service Revenue - recognized over time   313    889    1,518    2,543 
Total Revenue  $5,995   $6,884   $11,679   $22,543 

 

The Company operates in a highly regulated environment, primarily in the U.S. dermatology market, in which state regulatory approval is sometimes required prior to the customer being able to use the product. In cases where such regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained.

 

Deferred revenue activity as of September 30, 2026 was as follows:

             
(in thousands)  Product   Service   Total 
December 31, 2025  $351   $501   $852 
Revenue recognized   (536)   (1,518)   (2,054)
Amounts invoiced   390    1,597    1,987 
September 30, 2026  $205   $580   $785 

 

Remaining performance obligations of deposits for products have original expected durations of one year or less. Estimated service revenue to be recognized in the future related to the performance obligations that are unsatisfied (or partially unsatisfied) as of September 30, 2026 is as follows:

 

Year  Service Revenue 
2026 (October 1 - December 31, 2026)   278 
2027   302 
Total  $580 

 

For the nine months ended September 30, 2026 and 2025, the Company paid commissions for certain equipment sales. Because commissions are expected to be recovered through product revenue within one year, the Company expenses commissions as incurred.

 

In addition, the Company incurs commissions associated with equipment lease agreements, which are accounted for as initial direct costs and recorded in other noncurrent assets in the condensed consolidated balance sheets. The commission is capitalized at the commencement of the lease and recognized as an expense in selling and marketing expenses over the lease term.

 

Shipping and handling costs are expensed as incurred and are included in cost of sales.

 

Concentration

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable.

 

Two customers located in the U.S. accounted for 50% and 11% of revenue, respectively, for the three months ended September 30, 2026, and one customer located in the U.S. accounted for 59% of revenue for the three months ended September 30, 2025. One customer located in the U.S. accounted for 26% of revenue for the nine months ended September 30, 2026, and one customer located in the U.S. accounted for 62% of revenue for the nine months ended September 30, 2025. Four customers located in the U.S. accounted for 32%, 19%, 17%, and 16% of accounts receivable, respectively, as of September 30, 2026, and one customer located in the U.S. accounted for 65% of accounts receivable as of December 31, 2025.

 

7
 

 

Geographical Information

 

The following table illustrates total revenue for the three and nine months ended September 30, 2026 and 2025 by geographic region.

 

   For the Three Months Ended 
   September 30, 
(in thousands)  2026   2025 
United States  $5,170    86%  $6,393    93%
China   541    9%   456    7%
Other   284    5%   35    0%
Total Revenue  $5,995    100%  $6,884    100%

 

   For the Nine Months Ended 
   September 30, 
(in thousands)  2026   2025 
United States  $9,498    81%  $21,256    94%
China   1,556    13%   1,218    6%
Other   625    6%   69    0%
Total Revenue  $11,679    100%  $22,543    100%

 

Fair Value of Financial Instruments

 

Carrying amounts of cash equivalents, accounts receivable, accounts payable and the revolving credit facility approximate fair value due to their relative short maturities.

 

Fair Value Measurements

 

The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

 

Level 1 Inputs:

 

Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date.

 

  ● Level 1 assets may include listed mutual funds, ETFs and listed equities

 

Level 2 Inputs:

 

Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities that are not active; quotes from pricing services or brokers for which the Company can determine that orderly transactions took place at the quoted price or that the inputs used to arrive at the price are observable; and inputs other than quoted prices that are observable, such as models or other valuation methodologies.

 

  ● Level 2 assets may include debt securities and foreign currency exchange contracts that have inputs to the valuations that generally can be corroborated by observable market data.

 

8
 

 

Level 3 Inputs:

 

Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes.

 

  ● Level 3 assets include investments for which there is little, if any, market activity. These inputs require significant management judgment or estimation.

 

Significance of Inputs: The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument.

 

Cash, Restricted Cash, and Cash Equivalents

 

Cash and cash equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less.

 

Restricted cash represents $2.3 million maintained in a restricted money market account with City National Bank of Florida (“CNB”) as cash collateral for the Company’s obligations under its revolving credit facility. Restricted cash totalled $2.3 million as of September 30, 2026. There was no restricted cash balance as of December 31, 2025. See Note 3, Debt, for additional information regarding the revolving credit facility.

 

Accounts Receivable

 

The Company extends credit to customers based on an assessment of their financial condition and generally does not require collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company estimates future credit losses based on the age of customer receivable balances, collection history and forecasted economic trends. Future collections can be significantly different from historical collection trends or current estimates. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for expected credit losses was $0.1 million as of September 30, 2026 and December 31, 2025. Credit loss expense was $0 and $44 thousand for the three months ended September 30, 2026 and 2025, respectively, and $0 and $44 thousand for the nine months ended September 30, 2026 and 2025, respectively.

 

Notes Receivable

 

The Company provides financing to certain customers in connection with sales of its devices. Notes receivable bear fixed annual interest rates ranging from 1.5% to 6.0% and have original terms ranging from 36 to 72 months. Interest income from these arrangements is included in interest income, net, in the accompanying condensed consolidated statements of loss. As of September 30, 2026 and December 31, 2025, notes receivable totaled $3.3 million and $0.4 million, respectively.

 

The Company evaluates notes receivable arising from customer balances for expected credit losses in accordance with ASC 326, Financial Instruments—Credit Losses. The allowance for expected credit losses is determined based on historical collection experience, customer payment history, aging of outstanding balances, customer creditworthiness, and current and reasonably forecasted economic conditions. Management also considers customer-specific collection risks when evaluating expected losses over the remaining contractual life of the notes. The allowance is reassessed at each reporting date, with changes recognized in earnings.

 

Inventories

 

Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in, first-out method.

 

9
 

 

Earnings Per Share

 

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated using the same basis, adjusted for the effect of potentially dilutive common shares. The treasury stock method is used to determine the incremental shares attributable to stock options, restricted stock awards and warrants for purposes of diluted net loss per share. Potential common shares are excluded when their effect would be antidilutive.

 

The factors used in the net loss per share computation are as follows:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
(in thousands)  2026   2025   2026   2025 
Basic                
Net loss  $(1,493)  $(943)  $(12,868)  $(4,552)
Weighted average number of shares used in computing net loss per share – basic   16,462    16,320    16,462    16,327 
Net loss per share - basic  $(0.09)  $(0.06)  $(0.78)  $(0.28)
Diluted                    
Net loss  $(1,493)  $(943)  $(12,868)  $(4,552)
Weighted average number of shares used in computing net loss per share – basic   16,462    16,320    16,462    16,327 
Dilutive effects of:                    
Restricted stock awards   —    —    —    — 
Weighted average number of shares used in computing net loss per share – diluted   16,462    16,320    16,462    16,327 
Net loss per share - diluted  $(0.09)  $(0.06)  $(0.78)  $(0.28)
                     
The shares in full amount listed below were not included in the computation of diluted net loss per share because to do so would have been antidilutive for the periods presented:                    
Restricted stock awards   —    120,000    —    120,000 
Stock options   77,550    77,550    77,550    77,550 

 

Diluted net loss per share for the three and nine months ended September 30, 2026 and 2025 excludes the dilutive effect of any stock options or shares issued under restricted stock awards, as the inclusion would be antidilutive due to the Company’s net losses during the periods.

 

Leases

 

The Company evaluates arrangements at inception to determine if an arrangement is or contains a lease. Operating lease assets represent the Company’s right to control an underlying asset for the lease term, and operating lease liability represents the Company’s obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an incremental borrowing rate that the Company would expect to incur for a fully collateralized loan over a similar term under similar economic conditions to determine the present value of the lease payments. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets.

 

The lease payments used to determine the Company’s operating lease assets may include lease incentives, and stated rent increases are recognized in the Company’s operating lease assets in the Company’s condensed consolidated balance sheets. Operating lease assets are amortized to rent expense over the lease term and included in operating expenses in the condensed consolidated statements of loss.

 

For leases in which the Company is the lessor, the Company identifies the lease and non-lease components and allocates the contract consideration to the different components on a relative stand-alone selling price basis at lease inception. The Company uses a residual approach for the components when the stand-alone selling price is not directly observable or those for which the Company has not established a price.

 

10
 

 

The Company has elected the practical expedient to combine lease and non-lease components when the components qualify to be combined. Continuous supporting services are the primary non-lease components and are not predominant. As a result, the combined components are accounted for as a lease under ASC 842. The revenues from non-lease components that are not qualified to be combined are recognized when the services are rendered under ASC 606. The revenues from non-lease components were $0.1 million and $44 thousand for the three months ended September 30, 2026 and 2025, respectively, and $0.2 million for the nine months ended September 30, 2026 and 2025. 

 

For operating leases where the Company is the lessor, the Company recognizes the underlying assets and depreciates them over the estimated useful life, which is based upon the residual value expected at the end of the lease term. Lease income is recognized on a straight-line basis over the lease term when the lease payment is determined. Leasing revenue is not recognized when collection of all contractual rents over the term of the agreement is not probable. When collection is not probable, the Company limits the lease revenue to the lesser of the revenue recognized on a straight-line basis or cash basis. The lease income is included in revenues in the condensed consolidated statements of loss.

 

Variable lease payments associated with the leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented within revenues in the condensed consolidated statements of loss.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s condensed consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. 

 

In July 2025, the One Big Beautiful Bill Act (the “Tax Act”) was enacted, introducing various changes to U.S. corporate taxation, including provisions permitting 100% bonus depreciation on qualified property and immediate expensing of research and development expenditures. The effects of the Tax Act have been reflected in the Company’s results beginning in the third quarter of 2025. The Tax Act did not have a material impact on the Company’s income tax expense or effective tax rate for the period.

 

Uncertain tax positions are recognized in the condensed consolidated financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense.

 

Recent Accounting Pronouncements 

 

In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires entities to (i) disclose amounts of (a) purchase of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities, (ii) include certain amounts that are already required to be disclosed under current GAAP in the same disclosures as other disaggregation requirements, (iii) disclose a qualitative description of the amounts remaining in relevant expense captions that are not necessarily disaggregated quantitatively, and (iv) disclose the total amount of selling expenses on an interim and annual reporting basis and, in annual reporting periods, disclose the entity’s definition of selling expense. ASU No. 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU No. 2024-03 to determine the impact it may have on its condensed consolidated financial statements.

 

11
 

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270), which is intended to improve the navigability of the guidance in ASC 270, Interim Reporting, and clarify when it applies. Under the amendments, an entity is subject to ASC 270 if it provides interim financial statements and notes in accordance with GAAP. ASU No. 2025-11 also addresses the form and content of such financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU No. 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU No. 2025-11 to determine the impact it may have on its condensed consolidated financial statements. 

 

Note 2 — Property and Equipment

 

Property and equipment consist of the following:

 

   As of   As of    
   September 30,   December 31,   Estimated
(in thousands)  2026   2025   Useful Lives
            
Operations equipment  $1,317   $974   3-10 years
Equipment leased to customers   2,043    1,600   10 years
Tradeshow and demo equipment   1,100    1,184   3 years
Computer equipment   200    186   3 years
Research and development equipment   146    246   3 years
Subtotal   4,806    4,190    
Construction in progress   228    228    
Less accumulated depreciation   (2,372)   (2,442)   
Property and Equipment, Net  $2,662   $1,976    

 

Depreciation expense was $81 thousand and $98 thousand for the three months ended September 30, 2026 and 2025, respectively, and $0.3 million for the nine-month periods ended September 30, 2026 and 2025.

 

Note 3 — Debt 

 

At December 31, 2025, the Company was in default under its prior revolving credit facility with Fifth Third Bank, N.A. (“Fifth Third”), as successor by merger to Comerica Bank, for failing to maintain the required minimum profitability covenant. No borrowings were outstanding at any time under the Fifth Third facility. On May 8, 2026, the Company received notice from Fifth Third that the facility would terminate effective May 20, 2026, and the facility was terminated on that date.

 

On June 2, 2026, the Company entered into a revolving credit facility (the “CNB Credit Facility”) with CNB that provides for maximum borrowings of $15.0 million and matures on June 5, 2027, unless extended by mutual agreement. During the initial term, borrowings are limited to $2.0 million, and the remaining $13.0 million commitment is restricted. Any borrowings bear interest at the Secured Overnight Financing Rate plus 3.00% (or 6.90% at September 30, 2026). Interest is payable monthly, and all outstanding principal and accrued interest are due at maturity. The CNB Credit Facility is secured by $2.3 million of cash held in a restricted account and by a security interest in all of the Company’s assets (the “Collateral”). Under the CNB Credit Facility, the Company must obtain CNB’s prior written consent in order to take any of the following actions: (a) sell or transfer any of the Company’s assets outside the ordinary course of its business; (b) incur, create, assume, or permit to exist any other indebtedness (subject to certain exceptions); (c) encumber any of the Company’s assets with any liens other than liens in favor of CNB and certain other permitted liens; or (d) remove the Company’s current Chief Executive Officer, President, or Chief Financial Officer. The related loan agreement also includes customary representations and warranties and customary events of default, upon the occurrence of which, after any applicable grace period, CNB would have the ability to accelerate all outstanding advances, terminate the CNB Credit Facility, and exercise remedies with respect to the Collateral.

 

12
 

 

If the CNB Credit Facility is renewed and CNB makes the remaining $13.0 million commitment available, the Company will be required to maintain a minimum debt service coverage ratio of 1.50, tested quarterly beginning with the first fiscal quarter following such availability. The Company was not subject to this financial covenant as of September 30, 2026. At September 30, 2026, no borrowings were outstanding under the CNB Credit Facility.

 

Note 4 — Product Warranties

 

Changes in product warranty liability were as follows for the nine months ended September 30, 2026:

 

(in thousands)    
Balance, December 31, 2025  $275 
Warranties accrued during the period   209 
Payments on warranty claims   (182)
Balance, September 30, 2026  $302 

 

Note 5 — Leases

 

Operating Lease Agreements

 

The Company leases its headquarters office from an unrelated third party under a lease expiring in September 2027. The amortization expense of the right of use lease asset was $64 thousand and $61 thousand for the three months ended September 30, 2026 and 2025, respectively, and $0.2 million for the nine-month periods ended September 30, 2026 and 2025. In January 2025, the Company entered into a sublease agreement with an unrelated third party to lease a new office space which is adjacent to the current headquarters office. The sublease is effective from January 2025 to September 2027. 

 

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2026. 

 

Maturity of Operating Lease Liability  Amount 
2026 (October 1 - December 31, 2026)  $72 
2027   214 
Total undiscounted operating leases payments  $286 
Less: Imputed interest   (8)
Present Value of Operating Lease Liability  $278 
Operating lease liability, current portion  $278 
Operating lease liability, net of current portion  $— 
      
Other Information     
Weighted-average remaining lease term    1.00 year  
Weighted-average discount rate   5.32%

 

Cash paid for amounts included in the measurement of the operating lease liability was $0.2 million for the nine-month periods ended September 30, 2026 and 2025, and is included in cash flows from operating activities in the accompanying condensed consolidated statements of cash flows.

 

Operating lease cost recognized as expense was $68 thousand for the three-month periods ended September 30, 2026 and 2025, and $0.2 million for the nine-month periods ended September 30, 2026 and 2025. The financing component for operating lease liability represents the effect of discounting the operating lease payments to their present value.

 

13
 

 

Lessor Accounting

 

The Company, through its subsidiary, Sensus Healthcare Services, LLC, leases superficial radiotherapy equipment to dermatology clinics. These leases generally have an initial term of 60 months and automatically renew for a one-year period upon the expiration of the initial lease term. Payments due under the leases may be fixed or variable payments.

 

In July 2026, the Company began a third-party-funded equipment rental program with EverBank, N.A. Under the program, following delivery and of the equipment to a Company customer and the customer’s acceptance, EverBank provides upfront funding to the Company equal to the price of the equipment, and EverBank acquires title to the equipment. During the term of the rental, EverBank collects the related customer payments. Because the Company may reacquire the equipment for $1 at the end of the original lease term (subject to specific conditions), the arrangement is accounted for as a lease under ASC 842 rather than a sale. The lease is classified as an operating lease. The Company defers the consideration allocated to the equipment component and recognizes it as lease income on a straight-line basis over the original lease term, and accounts for consideration allocated to related services separately under ASC 606.

 

The component of lease income for the three and nine months ended September 30, 2026 is as follows:

 

                   
   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
(in thousands)  2026   2025   2026   2025 
Lease income - operating leases - fixed payments  $102   $64   $226   $192 
Lease income - operating leases - variable payments   299    466    842    895 
Total  $401   $530   $1,068   $1,087 

 

The future minimum fixed lease payments to be received under the lease agreements as of September 30, 2026 are as follows:

 

(in thousands)  Amount 
2026 (October 1 - December 31)   115 
2027   462 
2028   462 
2029   462 
2030   329 
Thereafter   134 
Total  $1,964 

 

Note 6 – Commitments and Contingencies

 

Manufacturing Agreement

 

The Company has a contract manufacturing agreement with an unrelated third party for the production and manufacture of the SRT-100 (and subsequently the SRT-100 Vision and the SRT-100+), in accordance with the Company’s product specifications. The agreement renews for successive one-year periods unless either party notifies the other party in writing, at least sixty days prior to the anniversary date of the agreement, that it will not renew the agreement. The Company or the manufacturer may terminate the agreement upon ninety days’ prior written notice.

 

The Company pays this manufacturer for finished goods in advance of the inventory being received. The Company paid this manufacturer $0.6 million and $0.9 million for finished goods for the three months ended September 30, 2026 and 2025, respectively, and $4.2 million and $5.8 million for the nine months ended September 30, 2026 and 2025, respectively. Finished goods of $0.6 million and $1.9 million were received from this manufacturer for the three months ended September 30, 2026 and 2025, respectively, and finished goods of $5.0 million and $8.4 million were received from this manufacturer for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026 and December 31, 2025, a prepayment related to these finished goods of $0 and $1.5 million, respectively, was presented in prepaid inventory in the accompanying condensed consolidated balance sheets. 

 

14
 

 

Legal Contingencies

 

The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies.

 

In August 2019, the Company received a Civil Investigative Demand from the Department of Justice (the “Department”) seeking documents and written responses in connection with an investigation of the billing to Medicare by a physician who had treated patients with the Company’s SRT-100. The Department subsequently advised the Company that it was considering expanding the investigation to determine whether the Company had any involvement in the physician’s use of certain reimbursement codes. The Company has fully cooperated with the Department. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other considerations, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Company’s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company. Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself. As of September 30, 2026, the Company was unable to estimate the cost, if any, associated with this matter   .

 

Note 7 — Stockholders’ Equity

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock. No shares of preferred stock were issued or outstanding at September 30, 2026 or December 31, 2025.

 

Treasury Stock

 

Treasury stock includes shares surrendered by employees for tax withholding on the vesting of restricted stock awards and shares repurchased in open market transactions. No shares were surrendered by employees for tax withholding for the three and nine months ended September 30, 2026 and 2025. During the three months ended September 30, 2026 and 2025, the Company did not repurchase any shares in open market transactions. During the nine months ended September 30, 2026 and 2025, the Company repurchased zero and 50,360 shares in open market transactions, respectively.

 

Note 8 — Equity-based Compensation

 

2016 and 2017 Equity Incentive Plans

 

The Company’s 2016 Equity Incentive Plan and the 2017 Incentive Plan, as amended in June 2023 and August 2025 (collectively, the “Plans”), provide for the issuance of up to 397,473 shares and 2,250,000 shares, respectively. In August 2025, the Company amended the 2017 Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,500,000 shares. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the Plans and the awards granted under the Plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting the Company’s common stock. The awards may be made in the form of restricted stock awards or stock options, among other things. As of September 30, 2026 and December 31, 2025, 1,676,973 and 1,675,223 shares were available to be granted under the Plans, respectively. 

 

15
 

 

On December 19, 2022, a total of 77,000 shares of restricted common stock were awarded to employees. The restricted shares vest 25% per year over a four-year period. The fair value of $6.40 per share, the stock price on grant date, is being recognized as expense on a straight-line basis over the vesting period. During the nine months ended September 30, 2026, 1,750 shares of unvested common stock were forfeited due to the termination of three employees. As of September 30, 2026, 63,750 of the shares issued on December 19, 2022 were vested or forfeited.

 

On January 11, 2024, 20,000 shares of restricted common stock with a fair value of $2.65 per share, the stock price on the grant date, were awarded to an employee. 10,000 of the shares vested and the expense related to these shares was recognized on the grant date. The remaining 10,000 shares vested in January 2025. The grant date fair value of $2.65 per share is being recognized as expense on a straight-line basis over the vesting period. As of September 30, 2026, the shares issued on January 11, 2024 were fully vested.

 

On December 17, 2024, 100,000 shares of restricted common stock with a fair value of $7.78 per share, the stock price on the grant date, were awarded to employees and directors. 10,000 of the shares issued to one individual vested and the expense related to these shares was recognized on the grant date. The remaining 30,000 shares awarded to the same individual vest over a three-year period. The remaining 60,000 shares awarded to other individuals vest 25% per year over a four-year period. The grant date fair value of $7.78 per share is being recognized as expense on a straight-line basis over the vesting period. During the three months ended September 30, 2026, none of the shares became vested or were forfeited. As of September 30, 2026, 50,000 of the shares issued on December 17, 2024 had been vested or forfeited.

 

On December 12, 2025, 40,000 shares of restricted common stock with a fair value of $3.83 per share, the stock price on the grant date, were issued to an employee. These shares vest 25% per year over a four-year period on each anniversary of the grant date. The grant date fair value of $3.83 per share is being recognized as expense on a straight-line basis over the vesting period of four years. As of September 30, 2026, none of the shares issued on December 12, 2025 had vested or been forfeited.

 

Restricted Stock

 

Restricted stock activity for the nine months ended September 30, 2026 is summarized below: 

 

       Weighted— 
       Average 
       Grant 
   Restricted   Date Fair 
Outstanding at  Stock   Value 
December 31, 2025   105,000   $6.08 
Granted   —    — 
Vested   —    — 
Forfeited   (1,750)   6.40 
September 30, 2026   103,250   $6.07 

 

The Company recognizes forfeitures as they occur. The reduction of stock compensation expense related to forfeitures was $0 for the three-month periods ended September 30, 2026 and 2025, and $0 and $5 thousand for the nine months ended September 30, 2026 and 2025, respectively.

 

Stock compensation expense related to restricted stock, excluding the recognition of forfeitures, was $70 thousand and $73 thousand for the three months ended September 30, 2026 and 2025, respectively, and $0.2 million for the nine-month periods ended September 30, 2026 and 2025.

 

Unrecognized stock compensation expense was $0.4 million as of September 30, 2026, which will be recognized over a weighted-average period of 2.4 years.

 

16
 

 

Stock Options

 

Stock options expire ten years after the grant date. Options that have been granted are exercisable and vest based on the terms of the related agreements.

 

The following table summarizes the Company’s stock options activity after December 31, 2025:

 

           Weighted— 
           Average 
       Weighted—   Remaining 
       Average   Contractual 
   Number of   Exercise   Term 
   Options   Price   (In Years) 
Outstanding - December 31, 2025   77,550   $5.55    2.08 
Granted   —    —    — 
Exercised   —    —    — 
Expired   —    —    — 
Outstanding - September 30, 2026   77,550   $5.55    1.33 
Exercisable - September 30, 2026   77,550   $5.55    1.33 

 

As of September 30, 2026, all outstanding stock options are fully vested. The stock options outstanding had no intrinsic value as of September 30, 2026 and December 31, 2025. 

 

Note 9 — Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

 

Effective income tax rates for interim periods are based upon the Company’s current estimated annual tax rate, which varies based upon the Company’s estimate of taxable earnings or loss and the mix of taxable earnings or loss in the various states in which the Company operates. In addition, the Company recognizes taxes related to unusual or infrequent items or resulting from a change in judgment regarding a position taken in a prior period as discrete items in the interim period in which the event occurs.

 

As of September 30, 2026, the Company continued recognition of a full valuation allowance against its net deferred tax assets that it recorded in the second quarter of 2026. In performing its quarterly assessment, management considered all available positive and negative evidence, including recent operating results, cumulative earnings history, expectations regarding future taxable income, the reversal of existing taxable temporary differences, and other relevant factors. Based on the weight of the available evidence as of September 30, 2026, management concluded that it was more likely than not that the Company's net deferred tax assets would not be realized. Accordingly, the valuation allowance reduced the net deferred tax assets to zero.

 

Income tax expense (benefit) was $0 and ($1.5) million for the three months ended September 30, 2026 and 2025, respectively. Income tax expense (benefit) was $4.1 million and ($2.1) million for the nine months ended September 30, 2026 and 2025, respectively. 

 

The Company's effective tax rates for the three months ended September 30, 2026 and 2025 were 0% and 60.9%, respectively, and (46.4%) and 31.4%, respectively, for the nine months ended September 30, 2026 and 2025. The effective tax rate for the three months ended September 30, 2026 was primarily attributable to the continued recognition of a full valuation allowance against the Company's net deferred tax assets, which was initially established during the second quarter of 2026. The decrease in the effective tax rate for the nine months ended September 30, 2026 compared to the corresponding prior-year period was primarily driven by the establishment of the valuation allowance during the second quarter of 2026.

 

17
 

 

The effective tax rate differs from the U.S. federal statutory rate for the three and nine months ended September 30, 2026, primarily due to the increase in valuation allowance, nondeductible expenses, state income taxes and the favorable impact of tax credits.

 

As of September 30, 2026, the Company’s U.S. federal and certain state tax returns remain subject to examination, beginning with those filed for the year ended December 31, 2018.

 

Note 10 — Segment Reporting

 

The Company has a single reportable segment focused on selling medical devices which are used to treat oncological and non-oncological skin conditions with SRT technology and providing services related to operating, maintaining, and repairing these devices.

 

The Company’s chief executive officer serves as the Company’s operating decision-maker (the “CODM”), assessing performance and making operating decisions using net income as the primary measure of profitability. The CODM is not regularly provided with specific segment expenses, but focuses on revenue, gross profit, and net income. Expense information, including cost of sales can be easily computed from the provided information. These segment (and consolidated) measures of profitability are shown in the condensed consolidated statements of loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.

 

Note 11 — Subsequent Events

 

The Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were issued for potential recognition or disclosure. The Company did not identify any subsequent events that would have required adjustment to or disclosure in the condensed consolidated financial statements.

 

18
 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with the information set forth within the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2025 Annual Report.

 

Overview

 

Sensus Healthcare, Inc. (together with its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, “Sensus,” “we,” “us,” “our,” or the “Company”) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on decades of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions of close to one million patients around the world.

 

Our business was organized in 2010 and the Company, incorporated in Delaware, completed its initial public offering in 2016. The Company operates from its corporate headquarters located in Boca Raton, Florida. In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly owned subsidiary that provides operational healthcare offerings to dermatology clinics in the form of equipment, radiation oncology and physicist oversight, and on-site device operation by radiotherapy technologists. The term the Company uses for this service model is the “Fair Deal Agreement.”

 

Segment Information

 

The Company manages its business globally within one reportable segment, which is consistent with how our management views the business, prioritizes investment and resource allocation decisions, and assesses operating performance.

 

Results of Operations

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
(in thousands, except shares and per share data)  2026   2025   2026   2025 
                 
Revenues  $5,995   $6,884   $11,679   $22,543 
Cost of sales   2,707    4,171    6,632    12,573 
Gross profit   3,288    2,713    5,047    9,970 
Operating expenses                    
General and administrative   2,253    1,917    6,079    6,111 
Selling and marketing   1,548    1,546    4,319    5,122 
Research and development   1,106    1,819    3,806    5,896 
Total operating expenses   4,907    5,282    14,204    17,129 
Loss from operations   (1,619)   (2,569)   (9,157)   (7,159)
Other income:                    
Interest income, net   126    160    368    528 
Other income, net   126    160    368    528 
Loss before income tax   (1,493)   (2,409)   (8,789)   (6,631)
(Benefit from) provision for income taxes   —    (1,466)   4,079    (2,079)
Net loss  $(1,493)  $(943)  $(12,868)  $(4,552)

 

19
 

 

Three months ended September 30, 2026 compared to the three months ended September 30, 2025

 

Revenues. Revenues were $6.0 million for the three months ended September 30, 2026 compared to $6.9 million for the three months ended September 30, 2025, a decrease of $0.9 million, or 13.0%. Although the number of units shipped increased (26 in the three months ended September 30, 2026, including 8 units backlog from the second quarter of 2026 but delivered in the current period, compared to 16 in the three months ended September 30, 2025), the decrease in revenue was primarily driven by product mix (the number of lower-priced SRT-100 units shipped versus the number of higher-priced SRT-100 Vision units shipped), which resulted in a lower average selling price per unit, as well as no sales in the current period to a historically large customer. In addition, 3 systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements compared to zero in the prior year period, for which revenue is recognized over the term of the agreement rather than at the time of shipment.

 

Cost of sales. Cost of sales was $2.7 million for the three months ended September 30, 2026 compared to $4.2 million for the three months ended September 30, 2025, a decrease of $1.5 million, or 35.7%. The decrease in cost of sales was primarily related to the product mix, including a higher proportion of SRT-100 units shipped compared to SRT-100 Vision units shipped, as SRT-100 units have a lower average cost per unit.

 

Gross profit. Gross profit was $3.3 million for the three months ended September 30, 2026 compared to $2.7 million for the three months ended September 30, 2025, an increase of $0.6 million, or 22.2%. Our overall gross profit percentage was 55.0% in the three months ended September 30, 2026 compared to 39.1% in the corresponding period in 2025. The increase in gross profit and margin was primarily driven by product mix, including a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-100 Vision units.

 

General and administrative. General and administrative expense was $2.3 million for the three months ended September 30, 2026 compared to $1.9 million for the three months ended September 30, 2025, an increase of $0.4 million, or 21.1%. The net increase in general and administrative expense was primarily due to higher legal and professional fees offset by reduction of insurance cost.

 

Selling and marketing. Selling and marketing expense was $1.5 million for the three-month periods ended September 30, 2026 and September 30, 2025.

 

Research and development. Research and development expense was $1.1 million for the three months ended September 30, 2026 compared to $1.8 million for the three months ended September 30, 2025, a decrease of $0.7 million, or 38.9%. The decrease was primarily due to a reduction in lobbying cost and reduced headcount.

 

Other income. Other income of $0.1 million and $0.2 million for the three months ended September 30, 2026 and 2025, respectively, relates primarily to interest income.

 

Income taxes. The Company's effective tax rates for the three months ended September 30, 2026 and 2025 were 0% and 60.9%, respectively. The effective tax rate for the three months ended September 30, 2026 was primarily attributable to the continued recognition of a full valuation allowance against the Company's net deferred tax assets, which was initially established during the second quarter of 2026.

 

The Company assesses the realizability of its deferred tax assets at each reporting date based on all available positive and negative evidence in accordance with ASC 740. Based on its assessment during the third quarter of 2026, management concluded that the full valuation allowance remained necessary. Accordingly, the Company maintained the valuation allowance as of September 30, 2026 and recognized no income tax expense for the three months then ended. Management will continue to assess the realizability of its deferred tax assets in future reporting periods, and changes in operating results, expectations of future taxable income, or other relevant evidence could result in adjustments to the valuation allowance.

 

20
 

 

Nine months ended September 30, 2026 compared to the nine months ended September 30, 2025

 

Revenues. Revenues were $11.7 million for the nine months ended September 30, 2026 compared to $22.5 million for the nine months ended September 30, 2025, a decrease of $10.8 million, or 48.0%. The decrease in revenue was primarily driven by a lower number of units shipped (51 in the nine months ended September 30, 2026, compared to 56 in the nine months ended September 30, 2025), the decrease in revenue was primarily driven by product mix (the number of SRT-100 units sold versus the number of SRT-100 Vision units sold), which resulted in a lower average selling price per unit, as well as no sales in the current period to a historically large customer. Further, 12 systems shipped during the period were under the Fair Deal Agreement program and rental arrangements compared to 10 in the prior year period, for which revenue is recognized over the term of the agreement rather than at the time of shipment.

 

Cost of sales. Cost of sales was $6.6 million for the nine months ended September 30, 2026 compared to $12.6 million for the nine months ended September 30, 2025, a decrease of $6.0 million, or 47.6%. The decrease in cost of sales was primarily related to a lower number of units sold.

 

Gross profit. Gross profit was $5.0 million for the nine months ended September 30, 2026 compared to $10.0 million for the nine months ended September 30, 2025, a decrease of $5.0 million, or 50.0%. Our overall gross profit percentage was 42.7% in the nine months ended September 30, 2026 compared to 44.4% in the corresponding period in 2025. The decrease in gross profit was primarily driven by product mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated with new system placements pursuant to the Fair Deal Agreements, which are recognized upfront while related revenue is recognized over the term of the agreement.

 

General and administrative. General and administrative expense was $6.1 million for the nine-month periods ended September 30, 2026 and 2025.

 

Selling and marketing. Selling and marketing expense was $4.3 million for the nine months ended September 30, 2026 compared to $5.1 million for the nine months ended September 30, 2025, a decrease of $0.8 million, or 15.7%. The decrease was primarily driven by a decrease in tradeshow expenses and clinical research costs, partially offset by an increase in commission expense.

 

Research and development. Research and development expense was $3.8 million for the nine months ended September 30, 2026 compared to $5.9 million for the nine months ended September 30, 2025, a decrease of $2.1 million, or 35.6%. The decrease was primarily due to the decrease in lobbying costs related to billing code reimbursement, the decrease in product development costs related to next-generation systems, and reduced headcount.

 

Other income. Other income of $0.4 million and $0.5 million for the nine months ended September 30, 2026 and 2025, respectively, relates primarily to interest income.

 

Income taxes. The effective tax rates for the nine months ended September 30, 2026 and 2025 were (46.4%) and 31.4%, respectively. The decrease in the effective tax rate for the nine months ended September 30, 2026 compared to the prior year period was primarily due to an increase in valuation allowance.

 

Financial Condition

 

The following discussion summarizes significant changes in assets and liabilities. Please see the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025 contained in Part I, Item 1 of this filing.

 

Assets

 

Cash, restricted cash, and cash equivalents were $12.9 million at September 30, 2026 compared to $22.1 million at December 31, 2025, a decrease of $9.2 million. The decrease was primarily attributable to net cash used in operating activities, including cash used to purchase inventory and an increase in customer notes receivable resulting from the Company offering customers more flexible payment terms for its products and services. See the section entitled “Inflation” below for details on the impacts of inflation on our business. See the section entitled “Cash flows” below for details on the change in cash, restricted cash, and cash equivalents during the nine months ended September 30, 2026.

 

21
 

 

Accounts receivable, net was $1.4 million at September 30, 2026 compared to $6.0 million at December 31, 2025, a decrease of $4.6 million. The decrease was primarily due to the decrease in sales and concentration of sales to the Company’s historically large customer, which have historically been subject to extended payment terms.

 

Inventories were $18.0 million at September 30, 2026 compared to $14.6 million at December 31, 2025, an increase of $3.4 million. The increase was primarily due to the anticipation of increasing future sales and inventory purchases made to qualify for volume discounts from the manufacturer.

 

Notes receivable were $3.3 million at September 30, 2026 compared to $0.4 million at December 31, 2025, an increase of $2.9 million. The increase was primarily due to additional financing provided by the Company to a customer in connection with the sale of the Company’s devices.

 

Liabilities

 

There were no borrowings outstanding under the revolving line of credit with City National Bank of Florida at September 30, 2026 or under the Company’s former revolving line of credit with Fifth Third at December 31, 2025. 

 

Liquidity and Capital Resources

 

In general terms, liquidity is a measurement of the Company’s ability to meet its cash needs. For the nine months ended September 30, 2026, funding was derived primarily from cash generated by the sale of equipment to our customers in the ordinary course of business and existing cash reserves. The Company believes that proceeds from maturing cash equivalents, as well as cash on hand are sufficient to meet operating capital and funding requirements for the next 12 months from the date this Quarterly Report was issued. The Company’s liquidity position and capital requirements may be impacted by a number of factors, including the following:

 

  ● ability to generate and increase revenue;

 

  ● fluctuations in gross margins, operating expenses and net results; and

 

  ● financial market instability or disruptions to the banking system due to bank failures.

 

The Company’s primary short-term capital needs, which are subject to change, include expenditures related to:

 

  ● expansion of sales and marketing activities; and

 

  ● expansion of research and development activities.

 

Sensus’s management regularly evaluates cash requirements for current operations, commitments, capital requirements and business development transactions, and may seek to raise additional funds for these purposes in the future. However, there can be no assurance that it will be able to raise such funds or the terms on which such funds may be raised, if at all.

 

22
 

 

Cash flows

 

The following table provides a summary of cash flows for the periods indicated:

 

   For the Nine Months Ended 
   September 30, 
(in thousands)  2026   2025 
Net cash provided by (used in):          
Operating activities  $(9,147)  $2,735 
Investing activities   (16)   (38)
Financing activities   —     (300)
Total  $(9,163)  $2,397 

 

Cash flows from operating activities

 

Net cash used in operating activities was $9.1 million for the nine months ended September 30, 2026, consisting of net loss of $12.9 million and an increase in net operating assets of $1.2 million, offset by non-cash activity of $5.0 million. Cash flows used in operating activities primarily include the receipt of revenues offset by the payment of operating expenses incurred in the normal course of business. Non-cash items consisted of stock-based compensation expense, deferred income taxes, provision for product warranties, amortization of right-of-use asset, and depreciation of property and equipment. Net cash provided by operating activities was $2.7 million for the nine months ended September 30, 2025, consisting of net loss of $4.6 million and non-cash activity of $(0.9) million, offset by a decrease in net operating assets of $8.2 million, primarily driven by a $10.4 million decrease in accounts receivable, a $2.0 million decrease in prepaid inventory, and a $3.7 million increase in inventories. Cash flows provided by operating activities primarily include the receipt of revenues offset by the payment of operating expenses incurred in the normal course of business. Non-cash items consisted of stock-based compensation expense, deferred income taxes, provision for product warranties, amortization of right-of-use asset, credit loss expense, and depreciation of property and equipment.

 

Cash flows from investing activities

 

Net cash used in investing activities for the nine months ended September 30, 2026 reflected $16 thousand of purchases of property and equipment. Net cash used in investing activities for the nine months ended September 30, 2025 reflected $38 thousand of purchases of property and equipment.

 

Cash flows from financing activities

 

No cash was used in financing activities for the nine months ended September 30, 2026 . Net cash used in financing activities for the nine months ended September 30, 2025 reflected $0.3 million of repurchases of common stock.

 

Inflation

 

During the third quarter of 2026, we continued to experience some increase in commodity and shipping prices and energy and labor costs which resulted in minor inflationary pressures across various parts of our business and operations, including on our customers, partners, and suppliers. We continue to monitor the impact of inflation and we are taking actions, such as ordering inventory in advance, to minimize its effects on our product cost and sales.

 

Indebtedness

 

Please see Note 3, Debt, to the condensed consolidated financial statements.

 

Contractual Obligations and Commitments

 

Please see Note 6, Commitments and Contingencies, to the condensed consolidated financial statements.

 

23
 

 

Critical Accounting Policies and Estimates

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. Management has not applied any critical accounting estimates but has identified revenue recognition policies as critical to understanding the Company’s financial condition and results of operations. For a detailed discussion on the application of these and other accounting policies, see the Note 1, Organization and Summary of Significant Accounting Policies to the consolidated financial statements included in the 2025 Annual Report.

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

Item 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of September 30, 2026, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of September 30, 2026, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

24
 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies. See Note 6, Commitments and Contingencies.

 

Item 1A. Risk Factors

 

As a smaller reporting company, we are not required to provide disclosure pursuant to this item in this Form 10-Q.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

(a) Sales of Unregistered Securities

 

There were no unregistered sales of securities during the three months ended September 30, 2026.

 

(b) Use of Proceeds from the Sale of Registered Securities

 

None.

 

(c) Purchases of Equity Securities by the Registrant and Affiliated Purchasers.

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

Item 5. Other Information

 

(c) Rule 10b5-1 Trading Plans

 

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.

 

25
 

 

Item 6. Exhibits

 

EXHIBIT INDEX

 

Exhibit No.   Description
31.1*   Certification of Joseph C. Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, Inc., Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
     
31.2*   Certification of Javier Rampolla, Chief Financial Officer of Sensus Healthcare, Inc., Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
     
32.1**   Certification of Joseph C. Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, Inc., Pursuant to 18 U.S.C. Section 1350.
     
32.2**   Certification of Javier Rampolla, Chief Financial Officer of Sensus Healthcare, Inc., Pursuant to 18 U.S.C. Section 1350.
     
101.INS*   Inline XBRL Instance Document.
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
104.*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*

**

Filed electronically herewith

Furnished electronically herewith.

  

26
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  SENSUS HEALTHCARE, INC.
   
Date: November 13, 2026 /s/ Joseph C. Sardano
  Joseph C. Sardano
  Chief Executive Officer
  (Principal Executive Officer)
   
Date: November 13, 2026 /s/ Javier Rampolla
  Javier Rampolla
  Chief Financial Officer
  (Principal Financial Officer and Principal Accounting Officer)

 

27

Keep reading